

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2004/0137471 A1	07-15-2004	Vickers <i>et al.</i>	All
	U2	US-2004/0242518 A1	12-02-2004	Chen <i>et al.</i>	All
	U3	US-2006/0068405 A1	03-30-2006	Diber <i>et al.</i>	All
	U4	US-5,831,069	11-03-1998	Barik	All
	U5	US-7,595,303	09-29-2009	Mohapatra <i>et al.</i>	All
	U6	US-7,655,772	02-02-2010	Mohapatra	All
	U7				
	U8				
	U9				
	U10				
	U11				
	U12				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ - Number ⁵ - Kind Code ⁶ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1445B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/544,146
Filing Date	May 5, 2006
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1635
Examiner Name	Richard A. Schnizer
Attorney Docket Number	USF.T193XC1

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Ambion (October 2002) TechNotes 9(5), "Selecting siRNA Sequences to Incorporate into the pSilencer Vectors" [online, retrieved on November 5, 2008] from internet <URL: http://www.ambion.com >, 2 pages.	
	R2	HU, W-Y. <i>et al.</i> "Inhibition of Retroviral Pathogenesis by RNA Interference" <i>Current Biology</i> , August 6, 2002, 12:1301-1311.	
	R3	JAYASENA, S.D. "Designer siRNAs to overcome the challenges from the RNAi pathway" <i>Journal of RNAi and Gene Silencing</i> , 2006, 2(1):109-117.	
	R4	KRUEGER, U. <i>et al.</i> "Insights into Effective RNAi Gained from Large-Scale siRNA Validation Screening" <i>Oligonucleotides</i> , 2007, 17:237-250.	
	R5	LUO, K.Q. <i>et al.</i> "The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region" <i>Biochemical and Biophysical Research Communications</i> , 2004, 318:303-310.	
	R6	RUTZ, S. <i>et al.</i> "Towards <i>in vivo</i> application of RNA interference - new toys, old problems" <i>Arthritis Research & Therapy</i> , 2004, 6(2):78-85.	
	R7	SCHUBERT, S. <i>et al.</i> "Local RNA Target Structure Influences siRNA Efficacy: Systematic Analysis of Intentionally Designed Binding Regions" <i>J Mol Biol</i> , 2005, 348:883-893.	
	R8	SCHUBERT, S. <i>et al.</i> "Oligonucleotide-Based Antiviral Strategies" <i>Handbook Exp Pharmacol</i> , 2006, 173:261-287.	
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	/Richard Schnizer/	Date Considered	06/28/2011
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./